News
Exploring the Intersection of Sensorineural Hearing Loss, Lassa Virus, and Vaccine Safety: Insights from the SPEAC Webinar
Did you know that up to 30% of Lassa fever survivors develop sensorineural hearing loss (SNHL)? This often-permanent condition not only affects quality of life but also raises important questions about vaccine safety. In our latest blog post, we explore insights from the recent SPEAC webinar, where global experts, including INSIS Co-lead Dr. Karina Top and PI Investigator Dr. Steven Black, discussed the immune mechanisms behind LASV-associated SNHL and the measures needed to ensure the safety of Lassa virus vaccines.
Discover how innovative technologies, multi-OMICs approaches, and robust clinical trial methodologies are paving the way for safer, more effective vaccines.
INSIS Featured on ICI Radio-Canada: Advancing Vaccine Safety Research
INSIS Shines on ICI Radio-Canada: Advancing Global Vaccine Safety
In January 2024, the International Network of Immunization Special Services (INSIS) was proudly featured on ICI Radio-Canada, CBC's national French-language network. The segment highlighted INSIS’s groundbreaking research into very rare side effects of COVID-19 vaccines, aiming to make future vaccines even safer and more effective.
Led by a global team of researchers, INSIS is dedicated to understanding these rare adverse reactions, which affect less than 0.001% of the population. Their work not only helps improve vaccine safety but also strengthens public trust in vaccines—tools that have saved millions of lives and remain essential in the fight against infectious diseases.
Learn more about this inspiring recognition and the critical work of INSIS.